CN108289844B - 包含非核苷逆转录酶抑制剂和聚(丙交酯-共-乙交酯)的注射溶液 - Google Patents
包含非核苷逆转录酶抑制剂和聚(丙交酯-共-乙交酯)的注射溶液 Download PDFInfo
- Publication number
- CN108289844B CN108289844B CN201680066785.XA CN201680066785A CN108289844B CN 108289844 B CN108289844 B CN 108289844B CN 201680066785 A CN201680066785 A CN 201680066785A CN 108289844 B CN108289844 B CN 108289844B
- Authority
- CN
- China
- Prior art keywords
- reverse transcriptase
- active ingredient
- pharmaceutically active
- nucleoside reverse
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
储备溶液 | 聚合物 | 聚合物重量 | n-甲基-吡咯烷酮重量 |
S 752a | RG 752S | 5.089g | 15.410g |
S 502a | RG 502 | 5.048 | 15.027g |
储备溶液 | 聚合物 | 聚合物重量 | n-甲基-吡咯烷酮重量 |
S 502b | RG 502 | 2.50g | 7.60g |
S 752b | RG 752S | 2.51g | 7.63g |
S 503b | RG 503 | 2.50g | 7.72g |
Claims (15)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562255866P | 2015-11-16 | 2015-11-16 | |
US62/255,866 | 2015-11-16 | ||
EP15197777 | 2015-12-03 | ||
EP15197777.4 | 2015-12-03 | ||
PCT/EP2016/077402 WO2017084973A1 (en) | 2015-11-16 | 2016-11-11 | Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108289844A CN108289844A (zh) | 2018-07-17 |
CN108289844B true CN108289844B (zh) | 2021-09-14 |
Family
ID=54780205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680066785.XA Active CN108289844B (zh) | 2015-11-16 | 2016-11-11 | 包含非核苷逆转录酶抑制剂和聚(丙交酯-共-乙交酯)的注射溶液 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10406098B2 (zh) |
EP (1) | EP3377039B1 (zh) |
JP (1) | JP6835841B2 (zh) |
KR (1) | KR102673927B1 (zh) |
CN (1) | CN108289844B (zh) |
CA (1) | CA3005313C (zh) |
IL (1) | IL259303B2 (zh) |
SG (1) | SG11201804037XA (zh) |
WO (1) | WO2017084973A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3897740A1 (en) * | 2018-12-21 | 2021-10-27 | The University Of Liverpool | Nrti therapies |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1474685A (zh) * | 2000-09-21 | 2004-02-11 | ������ʵ���ҹ�˾ | 更高效的利普安聚合物释放制剂 |
WO2009042194A2 (en) * | 2007-09-25 | 2009-04-02 | Trimeris, Inc. | Methods of synthesis for therapeuthic anti-hiv peptides |
CN102711834A (zh) * | 2008-12-24 | 2012-10-03 | 泰博特克药品公司 | 治疗hiv的可植入装置 |
CN103998069A (zh) * | 2011-10-17 | 2014-08-20 | 聚合-医药有限公司 | 可吸收的原位凝胶形成系统、其制备方法及用途 |
WO2015121413A1 (en) * | 2014-02-14 | 2015-08-20 | Aicuris Gmbh & Co. Kg | New active pharmaceutical ingredient combinations with compounds based on tri(hetero)aryl pyrazoles |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US6537972B1 (en) | 1997-06-02 | 2003-03-25 | Subsidiary No. 3., Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
EP1085846A2 (en) * | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US8470359B2 (en) * | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
CN1599598A (zh) | 2001-11-30 | 2005-03-23 | 美国辉瑞有限公司 | 骨生长促进性化合物的控释聚合组合物 |
JP2008519073A (ja) * | 2004-11-08 | 2008-06-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | チプラナビル及びエトラビリンの同時投与によるhiv感染症の治療法 |
TWI806081B (zh) * | 2014-07-11 | 2023-06-21 | 美商基利科學股份有限公司 | 用於治療HIV之toll樣受體調節劑 |
CA2961528A1 (en) * | 2014-09-26 | 2016-03-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions |
-
2016
- 2016-11-11 EP EP16795023.7A patent/EP3377039B1/en active Active
- 2016-11-11 JP JP2018525346A patent/JP6835841B2/ja active Active
- 2016-11-11 CA CA3005313A patent/CA3005313C/en active Active
- 2016-11-11 US US15/776,043 patent/US10406098B2/en active Active
- 2016-11-11 SG SG11201804037XA patent/SG11201804037XA/en unknown
- 2016-11-11 CN CN201680066785.XA patent/CN108289844B/zh active Active
- 2016-11-11 WO PCT/EP2016/077402 patent/WO2017084973A1/en active Application Filing
- 2016-11-11 KR KR1020187016902A patent/KR102673927B1/ko active IP Right Grant
-
2018
- 2018-05-13 IL IL259303A patent/IL259303B2/en unknown
-
2019
- 2019-07-25 US US16/521,760 patent/US20190343762A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1474685A (zh) * | 2000-09-21 | 2004-02-11 | ������ʵ���ҹ�˾ | 更高效的利普安聚合物释放制剂 |
WO2009042194A2 (en) * | 2007-09-25 | 2009-04-02 | Trimeris, Inc. | Methods of synthesis for therapeuthic anti-hiv peptides |
CN102711834A (zh) * | 2008-12-24 | 2012-10-03 | 泰博特克药品公司 | 治疗hiv的可植入装置 |
CN103998069A (zh) * | 2011-10-17 | 2014-08-20 | 聚合-医药有限公司 | 可吸收的原位凝胶形成系统、其制备方法及用途 |
WO2015121413A1 (en) * | 2014-02-14 | 2015-08-20 | Aicuris Gmbh & Co. Kg | New active pharmaceutical ingredient combinations with compounds based on tri(hetero)aryl pyrazoles |
Also Published As
Publication number | Publication date |
---|---|
IL259303B2 (en) | 2023-02-01 |
US20190343762A1 (en) | 2019-11-14 |
US10406098B2 (en) | 2019-09-10 |
US20180318211A1 (en) | 2018-11-08 |
SG11201804037XA (en) | 2018-06-28 |
JP6835841B2 (ja) | 2021-02-24 |
EP3377039A1 (en) | 2018-09-26 |
EP3377039B1 (en) | 2024-01-03 |
IL259303B (en) | 2022-10-01 |
IL259303A (en) | 2018-07-31 |
CN108289844A (zh) | 2018-07-17 |
WO2017084973A1 (en) | 2017-05-26 |
CA3005313C (en) | 2024-01-09 |
KR102673927B1 (ko) | 2024-06-10 |
KR20180080322A (ko) | 2018-07-11 |
CA3005313A1 (en) | 2017-05-26 |
JP2018533614A (ja) | 2018-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fakhari et al. | Engineered in-situ depot-forming hydrogels for intratumoral drug delivery | |
Zhao et al. | Challenges and potential for improving the druggability of podophyllotoxin-derived drugs in cancer chemotherapy | |
CN102740834B (zh) | 具有提升的水溶解度的含雷帕霉素的高分子纳米粒子注射剂型组合物及其制备方法,以及用于与放射线疗法联用的抗癌组合物 | |
Poláková et al. | Electrospun nanofibers for local anticancer therapy: Review of in vivo activity | |
US20210228564A1 (en) | Pyrvinium pamoate therapies and methods of use | |
US10525051B2 (en) | Compositions and methods for achieving sustained therapeutic drug concentrations in a subject | |
EP1991239B1 (en) | Doxorubicin formulations for anti-cancer use | |
PT1615640E (pt) | Combinações antineoplásticas | |
CN113226319B (zh) | 抗病毒前药及其纳米制剂 | |
JP6572256B2 (ja) | 液状生物学的活性成分の固形製剤を含む非静脈内剤型およびその使用 | |
KR102134585B1 (ko) | 보조 암 치료 방법 | |
US11857542B2 (en) | Treatment of migraine | |
AU2017319728A1 (en) | Depot systems comprising glatiramer acetate | |
EP2293795A1 (en) | Pharmaceutical combination | |
CN108289844B (zh) | 包含非核苷逆转录酶抑制剂和聚(丙交酯-共-乙交酯)的注射溶液 | |
AU2018242998B2 (en) | Glatiramer depot systems for treating progressive forms of multiple sclerosis | |
Kaminskas et al. | A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats | |
Yoshioka et al. | Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer | |
Chen et al. | Study on the Influencing Factors of Hypoglycemic Effect of Folate Targeted Polymersomes Encapsulating Insulin | |
KR20240050074A (ko) | 젬시타빈 및 라파마이신이 봉입된 온도민감성 plga-peg-plga 하이드로겔 및 이의 용도 | |
WO2023154464A1 (en) | Locally administered compositions and methods of use thereof | |
KR20230158088A (ko) | 리스페리돈 및 생분해성 중합체를 포함하는 지속성의 주사용 제제 | |
WO2023076332A1 (en) | Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor | |
CN109512821A (zh) | 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用 | |
KR20140118458A (ko) | Sda/pei 공중합체 및 이를 포함하는 유전자 전달체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1251186 Country of ref document: HK |
|
CB02 | Change of applicant information |
Address after: Darmstadt Applicant after: Roma Chemical Co.,Ltd. Address before: Darmstadt Applicant before: EVONIK ROHM GmbH Address after: Essen, Germany Applicant after: Evonik Operations Ltd. Address before: Essen, Germany Applicant before: EVONIK DEGUSSA GmbH |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200628 Address after: Essen, Germany Applicant after: EVONIK DEGUSSA GmbH Address before: Darmstadt Applicant before: Roma Chemical Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |